Moleculin reports FY2023 net loss of $29.8M; cash runway into Q4 2024

Moleculin Biotech, Inc.

Net loss $29.8M for fiscal year ended Dec 31, 2023; no revenue reported (pre-revenue biotech).
R&D expenses $19.5M, up $0.5M YoY driven by $1.5M WPD sublicense termination; G&A $10.0M, down $1.5M.
Cash and equivalents $23.6M at year-end; management expects runway into Q4 2024.
Closed $4.5M registered direct offering and private placement with institutional investor and insiders.
Positive interim Annamycin data in AML; plans to advance into pivotal Phase 2B/3 trial in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2023 results: net income $29.8 million.

Period: the fiscal year ended December 31, 2023
Net income: $29.8 million
Result: reported results

Exact text from the filing

Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-009047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.